AXOLTIS PHARMA has a total of 17 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2016. It filed its patents most often in Australia, United States and Canada. Its main competitors in its focus markets biotechnology and pharmaceuticals are SHANGHAI YIHAO BIOTECHNOLOGY CO LTD, SHANGHAI HENGRUN DASHENG BIOLOGICAL TECH CO LTD and FELDAN BIO INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | United States | 3 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | Israel | 2 | |
#7 | Republic of Korea | 2 | |
#8 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Microorganisms | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Bridon Dominique | 9 |
#2 | Gobron Stéphane | 8 |
#3 | Gobron Stephane | 8 |
#4 | Fauster Christian | 7 |
#5 | Cabart Frederic | 4 |
#6 | Cabart Frédéric | 3 |
#7 | Godfrin Yann | 1 |
#8 | Blanc Manuel | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021069497A1 | Systemic administration of peptides for the treatment of spinal cord injury and/or for remyelination | |
EP3548512A1 | Use of peptide compounds for promoting survival, growth and cell differentiation |